Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Marwan Fakih, Neil Howard Segal, Benjamin L. Schlechter, Thierry Andre, Filippo Pietrantonio, Benny Johnson, Alexander Vasilyev, Smitha S. Krishnamurthi, Salvatore Siena, Wells A. Messersmith, Virgilio Souza E Silva, Andrew Scott Paulson, Elena Elez, Cathy Eng, Sabine Tejpar, Michel Pierre Ducreux, Wei Wu, Joseph Elan Grossman, Eric Van Cutsem, Manuel Hidalgo
Institutions: City Of Hope National Medical Center, City of Hope, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Fondazione IRCCS Istituto Nazionale dei Tumori, The University of Texas MD Anderson Cancer Center, Agenus (United States), Russian Railways, Cleveland Clinic, University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University of Colorado Cancer Center, AC Camargo Hospital, Vall d'Hebron Hospital Universitari, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Universitair Ziekenhuis Leuven, KU Leuven, Université Paris-Saclay, Institut Gustave Roussy, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, NewYork–Presbyterian Hospital, Weill Cornell Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4406870002